You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. SBIR TOPIC 97- PHASE II- MINIMALLY INVASIVE TEST FOR CHEMOTHERAPY-INDUCED CARDIOTOXICITY

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NHLBI

    Cardiovascular toxicityCVTxis a serious short and long term complication of many anti cancer chemotherapeutic regimensZamoranoLancellotti et alIn this PhaseSBIR submission to continue the development and validation of Accel Diagnosticsminimally invasiverapidcost effective and connected blood testthe pScreen CVTx TMfor the early detection and continuous of chemotheropy induced CVTx

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Rapid, Accurate Point-of-Care Test for Gonorrhea and Determination of Antimicrobial Susceptibility

    SBC: AI BIOSCIENCES, INC.            Topic: NIAID

    Antimicrobial resistant gonorrheacaused by Neisseria gonorrhoeaeNGhas become an urgent threat for global public healthThe goal of this project is to develop a one hour point of care diagnosticPOCtest capable of identifying NGand determining the infecting strain s susceptibility to antibioticsAI Biosciences plans to achieve this goal by expanding the capability of its POC system being developed for ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Aptamer Affinity Reagents to Immune Targets in Non-human Disease Models

    SBC: BASE PAIR BIOTECHNOLOGIES INC            Topic: NIAID

    This goal of this program is to address the limited availability of reagentsantibodiesproteinsligandsfor the identification and discrimination of immune cells and the characterization of immune responses in nonmammalian models and mammalian models for which immunologic reagents are limitede gguinea pigferretcotton ratFor examplethe progression of disease that follows infection of guinea pigs with ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Fluorescent Qdot Immunochromatographic Test Strips for Influenza A B and Group A Strep

    SBC: NANOHMICS INC            Topic: ODCDC

    Nanohmics proposes to develop ultrasensitive and specific antibody based sandwich lateral flowLFtest strips for influenza A and B hemagglutinins and neuraminidasesas well as Group A StreptococcusSpyogenesfrom throat and nasal swabs or saliva samplesVery good LF test strips are already marketed for these highly important disease analytesBut to improve detectionNanohmics will incorporate fluorescent ...

    SBIR Phase I 2019 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. NCATS SBIR 2019 PHASE I PROPOSALS TOPIC 018 ENTITLED NON-PDMS BIOCOMPATIBLE ALTERNATIVES FOR ORGANS-ON-CHIPS

    SBC: LYNNTECH INC.            Topic: NIDA

    Microfluidic organ on a chipOOCsystems offer a distinct advantage over existing in vitro systems through incorporation of micro architecture to a cultured cell line sthat structurely and mechanically mimic more closely in vivo physiological conditions in an in vitro constructThese OOC devices are typically constructed from polydimethylsiloxanePDMShoweverPDMS has several drawbacks that can impact t ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Preformulation and formulation development of Fenrock, an Abuse-resistant Fentanyl Transdermal Patch

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIDA

    Project Summary Abstract Under this Fast Track proposalwe will develop Fenrockan abuse deterrent transdermal fentanyl patch based on our proprietary co crystal of naltrexoneNTXand its carefully selected conformermethyl furfuralMFFThis NTXMFFco crystalNTX Cohas the desired properties to stay in a crystalline solid form in the patch when applied to skin as intended but to dissociate to deliver NTX w ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Neonatal Abstinence Syndrome Therapy

    SBC: Mu Therapeutics Inc.            Topic: NIDA

    Neonatal Abstinence Syndrome (NAS) has skyrocketed in recent years as a result of the opioid epidemic plaguing this country. Since 2000, the number of babies affected by NAS has increased nearly 5-fold. Every 25 minutes a baby is born suffering from opioid withdrawal, often prematurely with developmental problems and potential long-term adverse effects including cognitive impairment. Approximately ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Solid-phase replication of long template libraries for NGS applications

    SBC: REDVAULT BIOSCIENCES LP            Topic: 100

    The rapid development of next generation sequencingNGStechnologies has allowed researchers to make unprecedented progress in the analysis of genomesthe results of which have profound implications for human healthThe ability to fully characterize genomes remains unrealizedhoweverdue in large part to our inability to reconcile sequence information over long distancesCurrent long readlong templateand ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. AmplideX DeepNet, a new paradigm for deep learning analytical tools in the molecular diagnostic space

    SBC: ASURAGEN, INC.            Topic: 400

    Project SummaryAn extensible analysis platform will be developed to accurately perform the automated genotyping of PCR capillary electrophoresisCEtraces for multiple disease associated short tandem repeaterSTRassaysThis study will evaluate the feasibility of developing generalizable and adaptive molecular analysis modelsand will ultimately establish a new paradigm for deep learning analytical tool ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government